CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma ...

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center have identified a ...

Our findings were actually not what we expected. As I said, our hypothesis was that the high number of cell replications required in the recipient compared to the donor would result in more mutations ...

Sitapriya Moorthi, a former postdoctoral researcher in the Berger Lab at Fred Hutch, puts it, “When we consider lung cancer in never ... despite the fact that these patients still reported some ...

Which medicine is best when you are affected by cancer? This can vary from person to person. A new method can help people with a specific type of blood cancer get the best medicine for them.

The treatment of chronic lymphocytic leukemia (CLL) consists of the continuous use of Bruton tyrosine kinase inhibitors (BTKis) such as ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib, or Bcl ...

Ghassan K. Abou-Alfa, MD, discusses the findings and key takeaways from the SUMMIT trial, which evaluated the use of neratinib for the treatment of patients with fibrolamellar carcinoma. Ghassan K.

Chronic lymphocytic leukemia (CLL) often causes overwhelming fatigue that does not go away with rest. A person may be able to manage fatigue due to CLL with lifestyle changes and dietary adjustments.

A study finds that staying active for 150 minutes weekly slashes the risk of 19 chronic diseases. Research at the University of Iowa reveals a clear connection between regular physical activity and ...

Study first author Jinsuke Nishino, M.D., Ph.D., a scientist in the Morrison Lab, first tested this hypothesis in mice. Consistent with the 2023 study, Dr. Nishino's findings showed that beta ...